Online inquiry

IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12252MR)

This product GTTS-WQ12252MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL6R gene. The antibody can be applied in Systemic sclerosis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3570
UniProt ID P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12252MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5657MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDX-011
GTTS-WQ3698MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ281MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ2994MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Angiocept
GTTS-WQ8366MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ15174MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA T1h
GTTS-WQ7353MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FPA-150
GTTS-WQ9223MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMMU-106
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW